File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer

TitleTargeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer
Authors
Keywordsbiomarker
early-stage
lung cancer
next-generation sequencing
relapse
Issue Date2018
PublisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html
Citation
Oncotarget, 2018, v. 9 n. 91, p. 36344-36357 How to Cite?
AbstractPurpose: The identification of genomic alterations related to recurrence in early-stage non-small cell lung cancer (NSCLC) patients may help better stratify high-risk individuals and guide treatment strategies. This study aimed to identify the molecular biomarkers of recurrence in early-stage NSCLC. Results: Of the 42 tumors evaluable for genomic alterations, TP53 and EGFR were the most frequent alterations with population frequency 52.4% and 50.0%, respectively. Fusion genes were detected in four patients, which had lower mutational burden and relatively better genomic stability. EGFR mutation and fusion gene were mutually exclusive in this study. CDKN2A, FAS, SUFU and SMARCA4 genomic alterations were only observed in the relapsed patients. Increased copy number alteration index was observed in early relapsed patients. Among these genomic alterations, early-stage NSCLCs harboring CDKN2A, FAS, SUFU and SMARCA4 genomic alterations were found to be significantly associated with recurrence. Some of these new findings were validated using The Cancer Genome Atlas (TCGA) dataset. Conclusions: The genomic alterations of CDKN2A, FAS, SUFU and SMARCA4 in early-stage NSCLC are found to be associated with recurrence, but confirmation in a larger independent cohort is required to define the clinical impact. Materials and Methods: Paired primary tumor and normal lung tissue samples were collected for targeted next-generation sequencing analysis. A panel targets exons for 440 genes was used to assess the mutational and copy number status of selected genes in three clinically relevant groups of stage I/II NSCLC patients: 1) Early relapse; 2) Late relapse; and 3) No relapse.
Persistent Identifierhttp://hdl.handle.net/10722/293333
ISSN
2015 Impact Factor: 5.008
2015 SCImago Journal Rankings: 2.294
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorCho, WCS-
dc.contributor.authorTan, KT-
dc.contributor.authorMa, VWS-
dc.contributor.authorLi, JYC-
dc.contributor.authorNgan, RKC-
dc.contributor.authorCheuk, W-
dc.contributor.authorYip, TTC-
dc.contributor.authorYang, YT-
dc.contributor.authorChen, SJ-
dc.date.accessioned2020-11-23T08:15:14Z-
dc.date.available2020-11-23T08:15:14Z-
dc.date.issued2018-
dc.identifier.citationOncotarget, 2018, v. 9 n. 91, p. 36344-36357-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/10722/293333-
dc.description.abstractPurpose: The identification of genomic alterations related to recurrence in early-stage non-small cell lung cancer (NSCLC) patients may help better stratify high-risk individuals and guide treatment strategies. This study aimed to identify the molecular biomarkers of recurrence in early-stage NSCLC. Results: Of the 42 tumors evaluable for genomic alterations, TP53 and EGFR were the most frequent alterations with population frequency 52.4% and 50.0%, respectively. Fusion genes were detected in four patients, which had lower mutational burden and relatively better genomic stability. EGFR mutation and fusion gene were mutually exclusive in this study. CDKN2A, FAS, SUFU and SMARCA4 genomic alterations were only observed in the relapsed patients. Increased copy number alteration index was observed in early relapsed patients. Among these genomic alterations, early-stage NSCLCs harboring CDKN2A, FAS, SUFU and SMARCA4 genomic alterations were found to be significantly associated with recurrence. Some of these new findings were validated using The Cancer Genome Atlas (TCGA) dataset. Conclusions: The genomic alterations of CDKN2A, FAS, SUFU and SMARCA4 in early-stage NSCLC are found to be associated with recurrence, but confirmation in a larger independent cohort is required to define the clinical impact. Materials and Methods: Paired primary tumor and normal lung tissue samples were collected for targeted next-generation sequencing analysis. A panel targets exons for 440 genes was used to assess the mutational and copy number status of selected genes in three clinically relevant groups of stage I/II NSCLC patients: 1) Early relapse; 2) Late relapse; and 3) No relapse.-
dc.languageeng-
dc.publisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html-
dc.relation.ispartofOncotarget-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectbiomarker-
dc.subjectearly-stage-
dc.subjectlung cancer-
dc.subjectnext-generation sequencing-
dc.subjectrelapse-
dc.titleTargeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer-
dc.typeArticle-
dc.identifier.emailNgan, RKC: rkcngan@hku.hk-
dc.identifier.authorityNgan, RKC=rp02371-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.18632/oncotarget.26349-
dc.identifier.pmid30555633-
dc.identifier.pmcidPMC6284742-
dc.identifier.scopuseid_2-s2.0-85057066110-
dc.identifier.hkuros319714-
dc.identifier.volume9-
dc.identifier.issue91-
dc.identifier.spage36344-
dc.identifier.epage36357-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats